Articles tagged with Ovarian Cancer
A retrospective analysis of 22 patients with brain metastases from ovarian cancer treated with Gamma Knife stereotactic radiosurgery (GKSRS) showed a high intracranial tumor control rate of 97.1% at 12 months post-treatment. No acute or chronic toxicity was observed in the study.
A new combination treatment strategy selectively targets ovarian tumor cells, reducing growth in preclinical models. The approach identifies effective regimens to treat genetically diverse cancers by blocking specific growth signaling pathways.
A new genetic marker, PPP2R1A mutations, has been linked to improved survival rates for patients treated with immunotherapy in ovarian and other cancers. Targeting this biomarker may further enhance treatment outcomes, suggesting a potential new therapeutic target.
The Association for Molecular Pathology publishes guidelines for detecting homologous recombination deficiency (HRD) in cancer. The report includes recommendations for clinical laboratories, addressing technical aspects of genomic instability and HRD analysis.
Researchers employed a novel validation-based insertional mutagenesis technique to identify genes conferring carboplatin resistance in human epithelial ovarian cancer cells. HN1L was found to enhance resistance by activating NF-κB signaling, and targeting this gene may represent a promising strategy for overcoming platinum resistance.
Mayo Clinic researchers have detected early, hidden changes in cells lining a patient's fallopian tubes, revealing signals that may point to the first signs of ovarian cancer. The study uses cutting-edge single-cell technologies to uncover developmental alterations in epithelial cells that signal high risk for lethal ovarian cancer.
Researchers found that it took 13 years for cervical cancer screenings to halve among women over 65, and even longer for prostate cancer screenings to decrease significantly. The study emphasizes the need for more effective tracking mechanisms to identify and reduce inappropriate screening practices.
A new study explains how the gene CDK12 drives high-grade serous tubo-ovarian carcinoma, a rare and aggressive form of ovarian cancer. Researchers discovered that inactivating CDK12 triggers an immune cell response and identified a partner gene, CDK13, as a target for a degrader or inhibitor.
The ESMO Gynaecological Cancers Congress 2025 will convene in Vienna, Austria, from June 19-21, featuring novel data on immunotherapy combinations and emerging treatment strategies for rare gynaecological cancers. The congress will also explore innovative approaches using antibody-drug conjugates.
Researchers discovered that blocking PRDX1 protein can make ovarian cancer cells more responsive to DNA-damaging platinum therapies. The study suggests targeting PRDX1 could be a viable strategy to improve chemotherapy efficacy.
Weill Cornell Medicine researchers Dr. Juan R. Cubillos-Ruiz and Dr. David Lyden have been awarded a $750,000 grant to study ovarian cancer, with a focus on harnessing immune cells and detecting the disease earlier. Their research aims to develop innovative strategies for eliminating metastatic tumors and preventing recurrence.
A real-world study of 1,752 patients with stage III or IV ovarian cancer found that adding bevacizumab to chemotherapy improved overall survival for those with advanced disease and residual cancer. Benefits were mostly seen in high-risk patients, not the general population.
Researchers found that phospholipids in ascites fluid disrupt immune cell function, particularly NK cells, leading to impaired anti-tumor activity. Blocking these lipids can restore NK cell activity, providing a promising therapeutic target.
Two new predictive algorithms use health data and blood tests to identify high-risk patients, offering improved accuracy in diagnosing cancers. The models identified additional medical conditions associated with increased cancer risk and new symptoms indicative of multiple cancer types.
A study found that removing ovaries and fallopian tubes in women with BRCA1 and BRCA2 genetic variants significantly reduces the risk of early death from cancer. This procedure, known as bilateral salpingo-oophorectomy (BSO), also decreases the risk of developing a second cancer without any serious side effects.
Researchers from the University of Southampton engineered a new type of super-strong antibody that triggers a stronger response from the immune system compared to naturally produced antibodies. The study confirms that making subtle increases in rigidity stimulates immune activity, creating a powerful immune response against disease.
Adaptive NK cells exhibit tumor-specific immune memory and cytotoxicity in ovarian cancer, making them promising for cancer treatment. The study challenges previous perceptions of NK cells, which have historically been considered only innate immune cells with no memory function against cancer.
Hyperbaric oxygen treatment has been shown to provide long-term relief for patients with late radiation-induced injuries, improving symptoms of urinary incontinence, bleeding, and severe pain. The treatment can lead to the healing of chronic injuries and allow patients to live a fully normal life.
Researchers have shed light on how a new type of antibody treatment works against ovarian cancer by reactivating patients' immune cells. The study shows that MOv18 IgE reverses the suppression of immune cells and induces them to kill cancer cells, providing new insights into this therapy.
A Phase 3 trial found that ChemoID improves objective response rates, median progression-free survival, and duration of response in patients with recurrent platinum-resistant ovarian cancer. The test identifies effective treatments by challenging cancer stem cells against specific anticancer drugs.
Researchers at MIT have developed a method to mass manufacture nanoparticles that target cancer cells, eliminating the need for manual polymer mixing and streamlining production. This approach integrates good manufacturing practice (GMP)-compliant processes, making it suitable for large-scale production of cancer treatments.
A 'master regulator' gene, ZNFX1, has been identified that may help guide treatment in patients with therapy-resistant ovarian cancer. The expression of this biomarker correlates with improved survival outcomes.
Patients from American Indian and Black communities are less likely to have elevated CA-125 levels at diagnosis, suggesting current thresholds may miss diverse patients. Inclusive diagnostic guidelines are needed to address disparities in ovarian cancer diagnosis and treatment.
A novel subset of progenitor cells, called high-risk MSCs, reside in the stroma and promote DNA damage and tumor growth. These cells play a critical role in the initiation of ovarian cancer, particularly in older women or those with BRCA mutations.
Researchers found that Black women have nearly identical mutations to other populations but experience lower survival rates due to clinical factors. The study highlights the importance of studying different population groups to improve ovarian cancer healthcare and develop targeted treatments.
A study of nearly 2,500 postmenopausal women found that taking more daily steps and engaging in moderate-to-vigorous physical activity were associated with a significantly reduced risk of death from cardiovascular disease. Even walking fewer than 5,000 steps per day showed a risk reduction.
Insilico Medicine has discovered a potent and selective CDK12/13 dual inhibitor, compound 12b, using AI-powered platforms. The compound shows significant efficacy in breast cancer and AML models without inducing side effects, paving the way for further therapeutic development.
Researchers at Tufts University have developed a cancer vaccine that amplifies the visibility of tumor antigens to the immune system, leading to potent responses and lasting immunological memory. The vaccine works against multiple solid tumors in animal models, including melanoma, triple-negative breast cancer, and ovarian cancer.
Researchers discovered noncoding cryptic peptides as an alternative source of target antigens for ovarian cancer. The findings could improve treatment approaches by mobilizing the immune system to attack tumor cells.
Researchers found that flagellin from the gut disrupts immune checkpoint treatment in ovarian cancer patients. Inhibiting this pathway may enhance clinical outcomes and save lives. The discovery could lead to novel therapies capable of targeting ovarian tumors.
Researchers found that women who had used the oral contraceptive pill had a lower risk of ovarian cancer, with a 39% reduced risk for those who had given birth to two or more children. The study also identified certain biomarkers and lifestyle factors associated with a lower risk of ovarian cancer, including lower body weight and short...
A mathematical modeling study suggests that removing fallopian tubes during other abdominal surgeries can lower ovarian cancer incidence by five percent. The approach could also reduce total healthcare costs in Germany, with estimated annual savings of over €10 million.
Researchers at UMass Amherst have developed a non-toxic bacterial therapy, BacID, to deliver cancer-fighting drugs directly into tumors. The therapy uses genetically engineered strains of Salmonella that can target tumors and control the release of cancer-fighting drugs inside cancer cells.
The new NCCN Guidelines for Patients: Genetic Testing for Hereditary Breast, Ovarian, Pancreatic, and Prostate Cancer provide evidence-based recommendations for assessing and testing for inherited genetic mutations. The resource aims to inform individuals about their cancer risks based on personal or family history.
A new study published in Nature Medicine shows that AI-based models can accurately identify ovarian cancer in ultrasound images, achieving an accuracy rate of 86.3%. The models also reduce the need for expert referrals and misdiagnosis rates by 63% and 18%, respectively.
Genetic testing for cancer risk should always include healthcare providers and genetic counseling to ensure users fully understand their results and receive proper guidance. The authors call on the FDA to provide clear rules for using these tests, particularly for minors.
Scientists at VCU Massey Comprehensive Cancer Center have discovered a new genetic code that recruits and deploys tumor cells to invade healthy organs. This breakthrough could offer groundbreaking insight into new treatment strategies targeting tumor growth in its earliest stages.
A new MRI-based imaging technique can rapidly assess ovarian cancer subtypes and their response to treatment, allowing for personalized treatment planning. The technique, called hyperpolarised carbon-13 imaging, distinguishes between two different subtypes of ovarian cancer and reveals their sensitivities to treatment.
Mesenchymal stem cells (MSCs) show promise in delivering treatments directly to cancer cells and boosting the immune system's fight against cancer. However, ongoing research highlights challenges related to MSC behavior, including variability in their effects and potential to create conditions that support tumor growth.
Researchers at The Wistar Institute have discovered a new combination therapy approach that shrinks tumors and improves survival rates in metastatic ovarian cancer. By activating myeloid cells, the treatment overcomes immunosuppression around tumors and makes them more receptive to chemotherapy.
The Wyss Institute's iNodes team has been awarded an ARPA-H Sprint for Women's Health to develop implantable immune organs for treating ovarian cancer. The iNodes concept is based on the formation of lymphoid organs in tumors, which can be reprogrammed to attack cancer cells and retain a long-term immune memory.
The National Comprehensive Cancer Network has updated its guidelines for genetic/familial high-risk assessment, incorporating the latest scientific research and expert recommendations to enhance screening practices and treatment options. The expanded guidelines cover various cancer types and provide guidance on genetic testing, heredit...
Researchers discovered that ovarian cancer produces IL-4 to create a protective environment, resisting immunotherapy. Blocking IL-4 with dupilumab-like drugs could enhance immunotherapy for ovarian cancer.
Researchers discovered a mechanism used by ovarian tumors to cripple immune cells by blocking the energy supply T cells depend on. The discovery points toward a promising new immunotherapy approach for treating ovarian cancer.
The researchers aim to establish targets for the vaccine by identifying proteins on the surface of early-stage ovarian cancer cells recognized by the immune system. If successful, clinical trials will begin to test the vaccine's effectiveness in preventing ovarian cancer, potentially offering a solution for women at high risk.
Researchers at MUSC Hollings Cancer Center have developed a new model for ovarian cancer that suggests serous uterine cancer may originate in the fallopian tubes, rather than the uterus. The model has already shown promising results in replicating high-grade serous ovarian and uterine cancers.
A new study found that the IOTA ADNEX ultrasound model can detect up to 96% of ovarian cancers in postmenopausal women, outperforming the current standard test. The research team recommends replacing the risk of malignancy (RMI1) test with the IOTA ADNEX model.
A blood test combining AI, cell-free DNA, and protein biomarkers shows high accuracy in detecting ovarian cancer. The test distinguishes between benign growths and cancerous tumors, offering a potential affordable screening method for widespread use.
Researchers identified over 3,000 harmful genetic changes in the RAD51C gene that increase ovarian cancer risk six-fold and breast cancer risk four-fold. These findings can help doctors and diagnostic laboratory scientists better assess cancer risk and provide more personalized care.
A recent study found that Chinese patients with ovarian cancer often carry a specific variant of the RAD51D gene, which can promote tumor growth. The variant also makes these patients more sensitive to PARP inhibitors, leading to a favorable prognosis and potential new treatment methods.
Researchers analyzed data from 1741 women diagnosed with high-grade serous ovarian cancer and found that symptom-triggered testing can lead to diagnosis of low-disease spread cases. In most cases, complete surgical removal of the cancerous tissue was possible, challenging the assumption that symptoms always signal advanced disease.
Researchers found that symptom-triggered testing can pick up early-stage aggressive ovarian cancer in 1 in 4 of those affected. The UK's protocol for picking up early-stage disease is an effective way to diagnose even early-stage ovarian cancer, with complete surgical removal possible in more than three quarters of women.
A study by the University of Gothenburg finds that removing Fallopian tubes during laparoscopic sterilization results in marginally more surgical complications than cutting them. The procedure may help protect against future ovarian cancer, a serious disease with limited early symptoms.
Researchers found that abnormal results from routine blood tests were linked to a higher risk of being diagnosed with cancer within a year. The study estimated that taking these results into account could lead to an extra six people with undiagnosed cancer being urgently referred for treatment.
A preclinical study led by Weill Cornell Medicine researchers found that the iron-chelating drug deferiprone can selectively target and kill ovarian cancer cells. By starving cancer cells of iron, deferiprone triggers a cellular stress response, prompting the immune system to attack them.
A study of nearly half a million women found that endometriosis was associated with a higher risk of ovarian cancer. The risk was particularly elevated among women with ovarian endometriomas or deep infiltrating endometriosis, with a 19-fold increased risk for certain types of ovarian cancer.
A Mayo Clinic study reveals that current genetic screening protocols fail to detect notable numbers of people carrying hereditary breast and ovarian cancer syndrome and Lynch syndrome mutations. The study identified 550 carriers of these mutations, with half being previously unaware of their risk.
A landmark study found women with severe endometriosis have a 10-fold increased risk of ovarian cancer, compared to those without the disease. The study analyzed over 78,000 women and revealed that those with severe endometriosis are also at higher risk for type I ovarian cancer.
Researchers at Dana-Farber Cancer Institute have developed CAR memory-like NK cells targeting the mesothelin protein, demonstrating superior antitumor activity in laboratory and animal models. The new cells maintained their effectiveness even after exposure to immunosuppressive ascitic fluid.
Dr. Sanaz Memarzadeh and her team aim to improve treatment outcomes for patients with platinum-resistant ovarian cancer using adoptive T-cell therapy and natural killer cells. They hope to identify new targets and biomarkers for effective treatments.